Whereas previous reports have demonstrated a difference in total CD8+ T cells in breast cancers across stage [53], age and menopause status [8,54,55], our findings indicate that a VCAN-status predicts more total CD8+ T cells across each of these clinical groups (Figure 3; Supplementary Figure S1). This evidence concerns the gene CD8A and breast cancer.